Skip to main content

Table 2 SARS-CoV-2 pandemic impact on ASPs

From: What is the impact of SARS-CoV-2 pandemic on antimicrobial stewardship programs (ASPs)? The results of a survey among a regional network of infectious disease centres

 

Values

ASPs during SARS-CoV-2 pandemic, n (%)

 Unchanged

2 (11.1)

 Reduced

9 (50)

 Suspended

7 (38.9)

ASPs post SARS-CoV-2 pandemic, n (%)

 Back to pre-pandemic activity

7 (38.9)

 Ongoing but are still reduced

7 (38.9)

 Remain suspended

4 (22.2)

Monitoring of high-cost antibiotic prescription, n (%)

6 (33.3)

Regular reports on antimicrobial usage, n (%)

6 (33.3)

Regular reports on the epidemiology of microbial isolates, n (%)

9 (50)

Ordinary wards converted into COVID-19 wards, n (%)

18 (100)

Number of beds dedicated to COVID-19 patients (April 2020)

 

 50

3 (16.7)

 50–100

10 (55.6)

 100–250

5 (27.8)

 250–500

0

 > 500

0

Number of beds dedicated to COVID-19 patients (August 2020)

 50

16 (88.9)

 50–100

1 (5.6)

 100–250

1 (5.6)

 250–500

0

  > 500

0

AMS team members shifted to clinical activity in COVID-19 wards, n (%)

13 (100) a

MDRO hospital acquired infections outbreaks in COVID-19 wards during the pandemic, n (%)

16 (88.9)

 Carbapenem-resistant Enterobacterales (CRE)

8 (44.4)

 Vancomycin-resistant enterococci (VRE)

11 (61.1)

 MDR A. baumanni

11 (61.1)

 MDR P. aeruginosa

11 (61.1)

 Candida auris

0

  1. AMS Antimicrobial stewardship, ASP Antimicrobial stewardship program, MDRO Multidrug resistant organisms
  2. aThe percentage calculated on the 13 ID centres where a formal AMS program has been implemented